Market Overview

Primex Pharmaceuticals appoints Steen Vangsgaard as Head of Sales

Share:

Swiss pharmaceutical company Primex Pharmaceuticals AG announces the
expansion of the leadership team with Mr. Steen Vangsgaard, appointed as
Head of Sales to the Executive Management Team led by CEO Kari Sarvanto.

Steen Vangsgaard has joined Primex Pharmaceuticals from Mylan
Pharmaceuticals, where he was VP, Area Director. Prior to Mylan, Mr.
Vangsgaard was EVP, Commercial Affairs at Bavarian-Nordic. He has
extensive international leadership experience in growing sales and
enhancing profitability of generics, branded pharmaceuticals and OTC
portfolios. Additionally, he has background in business development and
operational side of business.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180905005544/en/

Swiss pharmaceutical company Primex Pharmaceuticals AG announces the expansion of the leadership tea ...

Swiss pharmaceutical company Primex Pharmaceuticals AG announces the expansion of the leadership team with Mr. Steen Vangsgaard, appointed as Head of Sales to the Executive Management Team led by CEO Kari Sarvanto. (Photo: Business Wire)

"I look forward to working with our sales and distribution partners in
anticipation of making ADV6209 available to children who face surgical
intervention and emergency treatment. It is particularly gratifying to
join Primex at a time where we are preparing to help reduce pre- and
post-operative trauma in children and improve efficiency in trauma
centres and operating theatres," says Steen Vangsgaard.

At Primex, Mr. Vangsgaard is responsible for global sales. His first
effort will be the sales force and launch of ADV6209 in the Nordics. He
will be part of the Executive Team headed by CEO Kari Sarvanto in Zug,
Switzerland.

Mr. Sarvanto comments: "I am pleased that Primex can attract top talent
such as Steen. We are a fast growth company and with the impending
launch of ADV6209, the first oral paediatric anaesthetic in Europe, for
both premedication and procedural sedation, Steen will help us to
accelerate our launches in Europe, internationally and in the US."

About Primex Pharmaceuticals

Primex Pharmaceuticals aims to become the leading global innovative
anaesthesia company, and to expand in paediatric pharmaceuticals.

A portfolio of strong, trusted anaesthesia products from propofol-based
products acquired from Bayer, to a novel oral solution for paediatric
procedural sedation, helping patients undergo a wide range of medical
procedures. Primex Pharmaceuticals will continue to identify and acquire
new medications that complete the ‘Triad of Anaesthesia'. The group
includes a range of dental products and anaesthetics under the OGNA
brand.

Primex Pharmaceuticals' global partner network operates in over 40
countries. The company is headquartered in Switzerland; all Primex
products are manufactured in Europe. Primex Pharmaceuticals has proven
underlying business operations and historical strong revenue growth.

See more at www.primexpharma.com

View Comments and Join the Discussion!